Generation and characterisation of therapeutic tolerogenic dendritic cells for rheumatoid arthritis

Annals of the Rheumatic Diseases

Volumn 69, Issue 11, 2010, Pages 2042-2050

  Harry, Rachel A ^a   Anderson, Amy E ^a   Isaacs, John D ^a   Hilkens, Catharien M U ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

COLECALCIFEROL; DEXAMETHASONE; GAMMA INTERFERON; INTERLEUKIN 17; LIPID A; TOLL LIKE RECEPTOR 2;

ANTIGEN SPECIFICITY; ARTICLE; CD4+ T LYMPHOCYTE; CELL PROLIFERATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; FLOW CYTOMETRY; HUMAN; HUMAN CELL; MONOCYTE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RHEUMATOID ARTHRITIS; AUTOIMMUNE DISEASE; BIOSYNTHESIS; CULTURE TECHNIQUE; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; IMMUNOPHENOTYPING; LYMPHOCYTE ACTIVATION; T LYMPHOCYTE; TRANSPLANTATION;

ARTHRITIS, RHEUMATOID; AUTOIMMUNE DISEASES; CELL CULTURE TECHNIQUES; CELL PROLIFERATION; DENDRITIC CELLS; HUMANS; IMMUNE TOLERANCE; IMMUNOPHENOTYPING; INTERFERON-GAMMA; INTERLEUKIN-17; LYMPHOCYTE ACTIVATION; T-LYMPHOCYTES;

EID: 78149487035     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/ard.2009.126383     Document Type: Article

References (60)

1. Isaacs JD. T cell immunomodulation - the Holy Grail of therapeutic tolerance. Curr Opin Pharmacol 2007;7:418-25.
2. van Duivenvoorde LM, van Mierlo GJ, Boonman ZF, et al. Dendritic cells: vehicles for tolerance induction and prevention of autoimmune diseases. Immunobiology 2006;211:627-32.
3. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 1998;392:245-52.
4. Ohnmacht C, Pullner A, King SB, et al. Constitutive ablation of dendritic cells breaks self-tolerance of CD4 T cells and results in spontaneous fatal autoimmunity. J Exp Med 2009;206:549-59.
5. Thomson AW, Robbins PD. Tolerogenic dendritic cells for autoimmune disease and transplantation. Ann Rheum Dis 2008;67(Suppl 3):iii90-6.
6. Jonuleit H, Schmitt E, Steinbrink K, et al. Dendritic cells as a tool to induce anergic and regulatory T cells. Trends Immunol 2001;22:394-400. (Pubitemid 32673646)
7. Coates PT, Colvin BL, Kaneko K, et al. Pharmacologic, biologic, and genetic engineering approaches to potentiation of donor-derived dendritic cell tolerogenicity. Transplantation 2003;75(9 Suppl):32S-6S.
8. Morita Y, Yang J, Gupta R, et al. Dendritic cells genetically engineered to express IL-4 inhibit murine collagen-induced arthritis. J Clin Invest 2001;107:1275-84.
9. Kim SH, Kim S, Evans CH, et al. Effective treatment of established murine collagen-induced arthritis by systemic administration of dendritic cells genetically modified to express IL-4. J Immunol 2001;166:3499-505.
10. Steinbrink K, Wölfl M, Jonuleit H, et al. Induction of tolerance by IL-10-treated dendritic cells. J Immunol 1997;159:4772-80.
11. van Duivenvoorde LM, Han WG, Bakker AM, et al. Immunomodulatory dendritic cells inhibit Th1 responses and arthritis via different mechanisms. J Immunol 2007;179:1506-15.
12. van Duivenvoorde LM, Louis-Plence P, Apparailly F, et al. Antigen-specific immunomodulation of collagen-induced arthritis with tumor necrosis factor-stimulated dendritic cells. Arthritis Rheum 2004;50:3354-64.
13. Healy LJ, Collins HL, Thompson SJ. Systemic administration of tolerogenic dendritic cells ameliorates murine inflammatory arthritis. Open Rheumatol J 2008;2:71-80.
14. Bianco NR, Kim SH, Ruffner MA, et al. Therapeutic effect of exosomes from indoleamine 2,3-dioxygenase-positive dendritic cells in collagen-induced arthritis and delayed-type hypersensitivity disease models. Arthritis Rheum 2009;60:380-9.
15. Jaen O, Rullé S, Bessis N, et al. Dendritic cells modulated by innate immunity improve collagen-induced arthritis and induce regulatory T cells in vivo. Immunology 2009;126:35-44.
16. Chorny A, Gonzalez-Rey E, Fernandez-Martin A, et al. Vasoactive intestinal peptide induces regulatory dendritic cells with therapeutic effects on autoimmune disorders. Proc Natl Acad Sci USA 2005;102:13562-7.
17. Salazar L, Aravena O, Abello P, et al. Modulation of established murine collagen-induced arthritis by a single inoculation of short-term lipopolysaccharide-stimulated dendritic cells. Ann Rheum Dis 2008;67:1235-41.
18. Popov I, Li M, Zheng X, et al. Preventing autoimmune arthritis using antigen-specific immature dendritic cells: a novel tolerogenic vaccine. Arthritis Res Ther 2006;8:R141.
19. Adorini L. Tolerogenic dendritic cells induced by vitamin D receptor ligands enhance regulatory T cells inhibiting autoimmune diabetes. Ann N Y Acad Sci 2003;987:258-61.
20. Lau AW, Biester S, Cornall RJ, et al. Lipopolysaccharide-activated IL-10-secreting dendritic cells suppress experimental autoimmune uveoretinitis by MHCII-dependent activation of CD62L-expressing regulatory T cells. J Immunol 2008;180:3889-99.
21. Peng JC, Thomas R, Nielsen LK. Generation and maturation of dendritic cells for clinical application under serum-free conditions. J Immunother 2005;28:599-609.
22. de Vries IJ, Eggert AA, Scharenborg NM, et al. Phenotypical and functional characterization of clinical grade dendritic cells. J Immunother 2002;25:429-38.
23. Napoletano C, Pinto D, Bellati F, et al. A comparative analysis of serum and serum-free media for generation of clinical grade DCs. J Immunother 2007;30:567-76.
24. Anderson AE, Sayers BL, Haniffa MA, et al. Differential regulation of naïve and memory CD4+ T cells by alternatively activated dendritic cells. J Leukoc Biol 2008;84:124-33.
25. Anderson AE, Swan DJ, Sayers BL, et al. LPS activation is required for migratory activity and antigen presentation by tolerogenic dendritic cells. J Leukoc Biol 2009;85:243-50.
26. Hilkens CM, Isaacs JD, Thomson AW. Development of dendritic cell-based immunotherapy for autoimmunity. Int Rev Immunol 2010;29:156-83.
27. Hilkens CM, Isaacs JD. Tolerogenic dendritic cells in clinical practice. Open Arthritis Journal 2010;3:8-12.
28. Radstake TR, van Lent PL, Pesman GJ, et al. High production of proinflammatory and Th1 cytokines by dendritic cells from patients with rheumatoid arthritis, and down regulation upon FcgammaR triggering. Ann Rheum Dis 2004;63:696-702.
29. Radstake TR, Blom AB, Slöetjes AW, et al. Increased FcgammaRII expression and aberrant tumour necrosis factor alpha production by mature dendritic cells from patients with active rheumatoid arthritis. Ann Rheum Dis 2004;63:1556-63.
30. Figdor CG, de Vries IJ, Lesterhuis WJ, et al. Dendritic cell immunotherapy: mapping the way. Nat Med 2004;10:475-80.
31. Nestle FO, Banchereau J, Hart D. Dendritic cells: on the move from bench to bedside. Nat Med 2001;7:761-5.
32. Langenkamp A, Casorati G, Garavaglia C, et al. T cell priming by dendritic cells: thresholds for proliferation, differentiation and death and intraclonal functional diversification. Eur J Immunol 2002;32:2046-54.
33. Kalinski P, Schuitemaker JH, Hilkens CM, et al. Final maturation of dendritic cells is associated with impaired responsiveness to IFN-gamma and to bacterial IL-12 inducers: decreased ability of mature dendritic cells to produce IL-12 during the interaction with Th cells. J Immunol 1999;162:3231-6. (Pubitemid 29313569)
34. Hilkens CM, Kalinski P, de Boer M, et al. Human dendritic cells require exogenous interleukin-12-inducing factors to direct the development of naive T-helper cells toward the Th1 phenotype. Blood 1997;90:1920-6.
35. Mandron M, Ariès MF, Brehm RD, et al. Human dendritic cells conditioned with Staphylococcus aureus enterotoxin B promote TH2 cell polarization. J Allergy Clin Immunol 2006;117:1141-7.
36. Melkus MW, Estes JD, Padgett-Thomas A, et al. Humanized mice mount specific adaptive and innate immune responses to EBV and TSST-1. Nat Med 2006;12:1316-22.
37. Mingari MC, Cambiaggi A, Vitale C, et al. Effect of superantigens on human thymocytes: selective proliferation of V beta 2+ cells in response to toxic shock syndrome toxin-1 and their deletion upon secondary stimulation. Int Immunol 1996;8:203-9.
38. Ovali E, Dikmen T, Sonmez M, et al. Active immunotherapy for cancer patients using tumor lysate pulsed dendritic cell vaccine: a safety study. J Exp Clin Cancer Res 2007;26:209-14.
39. Curti A, Tosi P, Comoli P, et al. Phase I/II clinical trial of sequential subcutaneous and intravenous delivery of dendritic cell vaccination for refractory multiple myeloma using patient-specific tumour idiotype protein or idiotype (VDJ)-derived class I-restricted peptides. Br J Haematol 2007;139:415-24.
40. Motta MR, Castellani S, Rizzi S, et al. Generation of dendritic cells from CD14+ monocytes positively selected by immunomagnetic adsorption for multiple myeloma patients enrolled in a clinical trial of anti-idiotype vaccination. Br J Haematol 2003;121:240-50.
41. Makkouk A, Abdelnoor AM. The potential use of Toll-like receptor (TLR) agonists and antagonists as prophylactic and/or therapeutic agents. Immunopharmacol Immunotoxicol 2009;31:331-8.
42. Ismaili J, Rennesson J, Aksoy E, et al. Monophosphoryl lipid A activates both human dendritic cells and T cells. J Immunol 2002;168:926-32.
43. Mata-Haro V, Cekic C, Martin M, et al. The vaccine adjuvant monophosphoryl lipid A as a TRIF-biased agonist of TLR4. Science 2007;316:1628-32.
44. Henricson BE, Manthey CL, Perera PY, et al. Dissociation of lipopolysaccharide (LPS)-inducible gene expression in murine macrophages pretreated with smooth LPS versus monophosphoryl lipid A. Infect Immun 1993;61:2325-33.
45. Salkowski CA, Detore GR, Vogel SN. Lipopolysaccharide and monophosphoryl lipid A differentially regulate interleukin-12, gamma interferon, and interleukin-10 mRNA production in murine macrophages. Infect Immun 1997;65:3239-47.
46. Martin M, Michalek SM, Katz J. Role of innate immune factors in the adjuvant activity of monophosphoryl lipid A. Infect Immun 2003;71:2498-507.
47. Steinman RM, Hawiger D, Nussenzweig MC. Tolerogenic dendritic cells. Annu Rev Immunol 2003;21:685-711.
48. Rutella S, De Cristofaro R, Ferraccioli G. Function and dysfunction of dendritic cells in autoimmune rheumatic diseases. Hum Immunol 2009;70:360-73.
49. Rozkova D, Horvath R, Bartunkova J, et al. Glucocorticoids severely impair differentiation and antigen presenting function of dendritic cells despite upregulation of Toll-like receptors. Clin Immunol 2006;120:260-71.
50. Shibata M, Katsuyama M, Onodera T, et al. Glucocorticoids enhance Toll-like receptor 2 expression in human keratinocytes stimulated with Propionibacterium acnes or proinflammatory cytokines. J Invest Dermatol 2009;129:375-82.
51. Chamorro S, García-Vallejo JJ, Unger WW, et al. TLR triggering on tolerogenic dendritic cells results in TLR2 up-regulation and a reduced proinflammatory immune program. J Immunol 2009;183:2984-94.
52. Voigtländer C, Rössner S, Cierpka E, et al. Dendritic cells matured with TNF can be further activated in vitro and after subcutaneous injection in vivo which converts their tolerogenicity into immunogenicity. J Immunother 2006;29:407-15.
53. Dobrovolskaia MA, Vogel SN. Toll receptors, CD14, and macrophage activation and deactivation by LPS. Microbes Infect 2002;4:903-14.
54. Langenkamp A, Messi M, Lanzavecchia A, et al. Kinetics of dendritic cell activation: impact on priming of TH1, TH2 and nonpolarized T cells. Nat Immunol 2000;1:311-16.
55. Reis e Sousa C, Yap G, Schulz O, et al. Paralysis of dendritic cell IL-12 production by microbial products prevents infection-induced immunopathology. Immunity 1999;11:637-47.
56. Asong J, Wolfert MA, Maiti KK, et al. Binding and cellular activation studies reveal that toll-like receptor 2 can differentially recognize peptidoglycan from gram-positive and gram-negative bacteria. J Biol Chem 2009;284:8643-53.
57. Bosma BM, Metselaar HJ, Nagtzaam NM, et al. Dexamethasone transforms lipopolysaccharide-stimulated human blood myeloid dendritic cells into myeloid dendritic cells that prime interleukin-10 production in T cells. Immunology 2008;125:91-100.
58. Tsark EC, Wang W, Teng YC, et al. Differential MHC class II-mediated presentation of rheumatoid arthritis autoantigens by human dendritic cells and macrophages. J Immunol 2002;169:6625-33.
59. Tran CN, Davis MJ, Tesmer LA, et al. Presentation of arthritogenic peptide to antigen-specific T cells by fibroblast-like synoviocytes. Arthritis Rheum 2007;56:1497-506.
60. van Lierop MJ, den Hoed L, Houbiers J, et al. Endogenous HLA-DR-restricted presentation of the cartilage antigens human cartilage gp-39 and melanoma inhibitory activity in the inflamed rheumatoid joint. Arthritis Rheum 2007;56:2150-9.